DEK expression in Merkel cell carcinoma and small cell carcinoma

Journal of Cutaneous Pathology

Volumn 39, Issue 8, 2012, Pages 753-757

  Patel, Rajiv M ^a   Walters, Laura L ^a   Kappes, Ferdinand ^b,c   Mehra, Rohit ^a   Fullen, Douglas R ^a   Markovitz, David M ^a,b   Ma, Linglei ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

DEK; Merkel cell carcinoma; neuroendocrine carcinoma; small cell carcinoma

Indexed keywords

DEK PROTEIN, HUMAN; NONHISTONE PROTEIN; ONCOPROTEIN; TUMOR MARKER;

AGED; ARTICLE; CELL NUCLEUS; COMPARATIVE STUDY; FEMALE; HUMAN; LUNG TUMOR; LYMPH NODE; LYMPH NODE METASTASIS; MALE; MERKEL CELL TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; SKIN TUMOR; SMALL CELL CARCINOMA; TISSUE MICROARRAY;

AGED; AGED, 80 AND OVER; CARCINOMA, MERKEL CELL; CARCINOMA, SMALL CELL; CELL NUCLEUS; CHROMOSOMAL PROTEINS, NON-HISTONE; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; ONCOGENE PROTEINS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84864447044     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2012.01941.x     Document Type: Article

References (37)

1. Kappes F, Burger K, Baack M, Fackelmayer FO, Gruss C,. Subcellular localization of the human proto-oncogene protein DEK. J Biol Chem 2001; 276: 26317.
2. Gamble MJ, Fisher RP,. SET and PARP1 remove DEK from chromatin to permit access by the transcription machinery. Nat Struct Mol Biol 2007; 14: 548.
3. Khodadoust MS, Verhaegen M, Kappes F, et al. Melanoma proliferation and chemoresistance controlled by the DEK oncogene. Cancer Res 2009; 69: 6405.
4. Riveiro-Falkenbach E, Soengas MS,. Control of tumorigenesis and chemoresistance by the DEK oncogene. Clin Cancer Res 2010; 16: 2932.
5. Shibata T, Kokubu A, Miyamoto M, et al. DEK oncoprotein regulates transcriptional modifiers and sustains tumor initiation activity in high-grade neuroendocrine carcinoma of the lung. Oncogene 2010; 29: 4671.
6. Kappes F, Waldmann T, Mathew V, et al. The DEK oncoprotein is a Su(var) that is essential to heterochromatin integrity. Genes Dev 2011; 25: 673.
7. Wise-Draper TM, Allen HV, Thobe MN, et al. The human DEK proto-oncogene is a senescence inhibitor and an upregulated target of high-risk human papillomavirus E7. J Virol 2005; 79: 14309.
8. Wise-Draper TM, Mintz-Cole RA, Morris TA, et al. Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivo. Cancer Res 2009; 69: 1792.
9. von Lindern M, Fornerod M, van Baal S, et al. The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA. Mol Cell Biol 1992; 12: 1687.
10. Fornerod M, Boer J, van Baal S, et al. Relocation of the carboxyterminal part of CAN from the nuclear envelope to the nucleus as a result of leukemia-specific chromosome rearrangements. Oncogene 1995; 10: 1739.
11. Ageberg M, Drott K, Olofsson T, Gullberg U, Lindmark A,. Identification of a novel and myeloid specific role of the leukemia-associated fusion protein DEK-NUP214 leading to increased protein synthesis. Genes Chromosomes Cancer 2008; 47: 276.
12. Abba MC, Sun H, Hawkins KA, et al. Breast cancer molecular signatures as determined by SAGE: correlation with lymph node status. Mol Cancer Res 2007; 5: 881.
13. Carro MS, Spiga FM, Quarto M, et al. DEK expression is controlled by E2F and deregulated in diverse tumor types. Cell Cycle 2006; 5: 1202.
14. Han S, Xuan Y, Liu S, et al. Clinicopathological significance of DEK overexpression in serous ovarian tumors. Pathol Int 2009; 59: 443.
15. Kondoh N, Wakatsuki T, Ryo A, et al. Identification and characterization of genes associated with human hepatocellular carcinogenesis. Cancer Res 1999; 59: 4990.
16. Kroes RA, Jastrow A, McLone MG, et al. The identification of novel therapeutic targets for the treatment of malignant brain tumors. Cancer Lett 2000; 156: 191.
17. Orlic M, Spencer CE, Wang L, Gallie BL,. Expression analysis of 6p22 genomic gain in retinoblastoma. Genes Chromosomes Cancer 2006; 45: 72.
18. Sanchez-Carbayo M, Socci ND, Lozano JJ, et al. Gene discovery in bladder cancer progression using cDNA microarrays. Am J Pathol 2003; 163: 505.
19. Wu Q, Li Z, Lin H, Han L, Liu S, Lin Z,. DEK overexpression in uterine cervical cancers. Pathol Int 2008; 58: 378.
20. Allen PJ, Bowne WB, Jaques DP, Brennan MF, Busam K, Coit DG,. Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J Clin Oncol 2005; 23: 2300.
21. Lemos B, Nghiem P,. Merkel cell carcinoma: more deaths but still no pathway to blame. J Invest Dermatol 2007; 127: 2100.
22. Heath M, Jaimes N, Lemos B, et al. Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. J Am Acad Dermatol 2008; 58: 375.
23. Santos GC, Zielenska M, Prasad M, Squire JA,. Chromosome 6p amplification and cancer progression. J Clin Pathol 2007; 60: 1.
24. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006; 24: 4539.
25. Namiki T, Yanagawa S, Izumo T, et al. Genomic alterations in primary cutaneous melanomas detected by metaphase comparative genomic hybridization with laser capture or manual microdissection: 6p gains may predict poor outcome. Cancer Genet Cytogenet 2005; 157: 1.
26. Hanly AJ, Elgart GW, Jorda M, Smith J, Nadji M,. Analysis of thyroid transcription factor-1 and cytokeratin 20 separates Merkel cell carcinoma from small cell carcinoma of lung. J Cutan Pathol 2000; 27: 118.
27. Kappes F, Khodadoust MS, Yu L, et al. DEK expression in melanocytic lesions. Hum Pathol 2011; 42: 932.
28. Kargi A, Gurel D, Tuna B,. The diagnostic value of TTF-1, CK 5/6, and p63 immunostaining in classification of lung carcinomas. Appl Immunohistochem Mol Morphol 2007; 15: 415.
29. Asioli S, Righi A, de Biase D, et al. Expression of p63 is the sole independent marker of aggressiveness in localised (stage I-II) Merkel cell carcinomas. Mod Pathol 2011; 24: 1451.
30. Wise-Draper TM, Morreale RJ, Morris TA, et al. DEK proto-oncogene expression interferes with the normal epithelial differentiation program. Am J Pathol 2009; 174: 71.
31. Duncavage EJ, Zehnbauer BA, Pfeifer JD,. Prevalence of Merkel cell polyomavirus in Merkel cell carcinoma. Mod Pathol 2009; 22: 516.
32. Feng H, Shuda M, Chang Y, Moore PS,. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 2008; 319: 1096.
33. Garneski KM, Warcola AH, Feng Q, Kiviat NB, Leonard JH, Nghiem P,. Merkel cell polyomavirus is more frequently present in North American than Australian Merkel cell carcinoma tumors. J Invest Dermatol 2009; 129: 246.
34. Houben R, Adam C, Baeurle A, et al. An intact retinoblastoma protein-binding site in Merkel cell polyomavirus large T antigen is required for promoting growth of Merkel cell carcinoma cells. Int J Cancer 2012; 130: 847.
35. Helmbold P, Lahtz C, Herpel E, Schnabel PA, Dammann RH,. Frequent hypermethylation of RASSF1A tumour suppressor gene promoter and presence of Merkel cell polyomavirus in small cell lung cancer. Eur J Cancer 2009; 45: 2207.
36. Jung HS, Choi YL, Choi JS, et al. Detection of Merkel cell polyomavirus in Merkel cell carcinomas and small cell carcinomas by PCR and immunohistochemistry. Histol Histopathol 2011; 26: 1231.
37. Wetzels CT, Hoefnagel JG, Bakkers JM, Dijkman HB, Blokx WA, Melchers WJ,. Ultrastructural proof of polyomavirus in Merkel cell carcinoma tumour cells and its absence in small cell carcinoma of the lung. PLoS One 2009; 4: e4958.